Loading...
XNAS
ZURA
Market cap80mUSD
Jul 14, Last price  
1.30USD
1D
-0.76%
1Q
14.04%
IPO
-82.04%
Name

Zura Bio Ltd

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
Net income
-45m
L-24.81%
8,416,7103,549,127-60,360,000-45,386,000
CFO
-28m
L+86.50%
-1,098,146-1,071,033-15,054,000-28,076,000

Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
IPO date
Jul 16, 2021
Employees
Domiciled in
US
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2024‑122023‑122022‑122022‑032021‑12
Income
Revenues
Cost of revenue
55,189
43,999
26,364
Unusual Expense (Income)
NOPBT
(55,189)
(43,999)
(26,364)
NOPBT Margin
Operating Taxes
(7,017)
(203)
(570)
Tax Rate
NOPAT
(48,172)
(43,796)
(26,364)
Net income
(45,386)
-24.81%
(60,360)
-1,800.70%
3,549
-57.83%
Dividends
Dividend yield
Proceeds from repurchase of equity
60,757
116,407
10,000
BB yield
-32.37%
-75.39%
Debt
Debt current
356
Long-term debt
12,500
Deferred revenue
Other long-term liabilities
990
(8,072)
Net debt
(176,498)
(99,806)
12,842
Cash flow
Cash from operating activities
(28,076)
(15,054)
(1,071)
CAPEX
(75)
(12,000)
Cash from investing activities
(5,075)
(8,000)
(12,000)
Cash from financing activities
109,843
121,293
356
FCF
(48,263)
(58,225)
(11,935)
Balance
Cash
176,498
99,806
14
Long term investments
Excess cash
176,498
99,806
14
Stockholders' equity
(144,227)
(83,269)
119,319
Invested Capital
304,246
163,810
(9,214)
ROIC
286.12%
ROCE
EV
Common stock shares outstanding
75,071
33,064
17,250
Price
2.50
-46.47%
4.67
 
Market cap
187,677
21.55%
154,409
 
EV
22,842
74,824
EBITDA
(55,180)
(43,999)
(26,364)
EV/EBITDA
Interest
Interest/NOPBT